Work

Hypertension and Subclinical Vascular Damage After Allogeneic Hematopoietic Stem Cell Transplantation

Year: 2026

Type: article

Abstract: BACKGROUND: Patients with hematological malignancies undergoing allogeneic hematopoietic stem cell transplantation (alloHSCT) face a higher risk of premature cardiovascular disease that may partly be explained by hypertension. OBJECTIVES: The authors studied the prevalence of hypertension in alloHSCT survivors at least 1 year post-transplant. METHODS: Two hundred survivors were clinically screened for hypertension. Hypertension was defined according to established ambulatory blood pressure monitoring (ABPM) thresholds. Subclinical vascular damage was assessed through carotid intima-media thickness by ultrasonography of the carotid arteries, pulse wave velocity, and renal function. RESULTS: ; P = 0.010) compared to normotensive patients. In the logistic regression model, both age in years (OR: 1.03; 95% CI: 1.01-1.05; P = 0.019) and family history of cardiovascular disease and/or premature death (OR: 2.28; 95% CI: 1.17-4.44; P = 0.016) were independently associated with hypertension. CONCLUSIONS: Hypertension is highly prevalent, underrecognized, and undertreated in alloHSCT survivors and is cross-sectionally associated with subclinical vascular and renal organ damage.

Source: JACC Advances

DOI: 10.1016/j.jacadv.2026.103314